Effect of the Aquaretic Tolvaptan on Nitric Oxide System

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions

Autosomal Dominant Polycystic Kidney Disease

Interventions

DRUG

Tolvaptan

60 mg Tolvaptan pr day for 1 day

DRUG

Placebo

1 tablet Unikalk pr day for 1 day

Trial Locations (1)

Department of Medical Research and Medicine, Holstebro Regional Hospital, Holstebro

All Listed Sponsors

collaborator

Aarhus University Hospital

OTHER

lead

Regional Hospital Holstebro

OTHER

NCT02527863 - Effect of the Aquaretic Tolvaptan on Nitric Oxide System | Biotech Hunter | Biotech Hunter